Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427128 · ClinicalTrials.gov registry record · Phase 4
Prozac Treatment of Major Depression: Discontinuation Study
A Phase 4 study of Major Depression, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 627
- Enrollment target
- 2
- Study locations
NCT00427128 is a Phase 4 study of Major Depression that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 627 participants, above the 305-participant average among 28 other Major Depression trials with a reported enrollment target (106% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00427128, a Phase 4 study of Major Depression, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 627 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study randomized two stratifications of acute phase MDD SSRI responders, categorized as having either "true drug" response or "placebo response" pattern, to continuation with SSRI vs placebo in a double-blind trial to determine if stratification category predicted continuation outcome.
Conditions Studied
Interventions
- DRUG placebo
- DRUG fluoxetine
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 1995-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427128
The ClinicalTrials.gov registry entry for NCT00427128 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 305-participant average among 28 other Major Depression trials with a reported enrollment target (106% higher). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00427128 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00427128 about?
NCT00427128 is a clinical study titled "Prozac Treatment of Major Depression: Discontinuation Study". This study randomized two stratifications of acute phase MDD SSRI responders, categorized as having either "true drug" response or "placebo response" pattern, to continuation with SSRI vs placebo in a double-blind trial to determine if stratification category predicted continuation outcome.
What is the current status of trial NCT00427128?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 627 participants. The study started on 1995-11. Estimated completion is 2003-03.
What conditions does trial NCT00427128 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00427128?
The interventions under investigation include: placebo (DRUG), fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00427128?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00427128 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.